Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
12.00
+0.39 (3.36%)
Mar 13, 2026, 4:00 PM EDT - Market closed
Xencor Employees
Xencor had 260 employees as of December 31, 2025. The number of employees increased by 10 or 4.00% compared to the previous year.
Employees
260
Change (1Y)
10
Growth (1Y)
4.00%
Revenue / Employee
$482,985
Profits / Employee
-$353,550
Market Cap
880.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 260 | 10 | 4.00% | 260 | 0 |
| Dec 31, 2024 | 250 | -30 | -10.71% | 250 | 0 |
| Dec 31, 2023 | 280 | -1 | -0.36% | 280 | 0 |
| Dec 31, 2022 | 281 | 27 | 10.63% | 281 | 0 |
| Dec 31, 2021 | 254 | 52 | 25.74% | 254 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Valneva SE | 700 |
| MannKind | 592 |
| UroGen Pharma | 291 |
| KalVista Pharmaceuticals | 270 |
| Sana Biotechnology | 142 |
| Adlai Nortye | 123 |
| Annexon | 99 |
XNCR News
- 2 days ago - Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 9 days ago - Xencor Announces Change to Ultomiris® Royalty Revenue Forecast - Business Wire
- 16 days ago - Xencor Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 18 days ago - Xencor to Participate at Upcoming Investor Conferences - Business Wire
- 2 months ago - Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - Business Wire
- 2 months ago - Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 - Seeking Alpha
- 3 months ago - Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - Business Wire
- 4 months ago - Xencor Reports Third Quarter 2025 Financial Results - Business Wire